Tevogen Bio, a clinical stage biotechnology company, has expanded its leadership team with two new executives to support the biotech’s rapid operational growth, manufacturing readiness, and the continued development and utilization of its next generation precision T cell platform technology.
 
New hires include:

Stephen Chen, Chief Technical Officer

Stephen Chen, MBA, has more than 18 years of biotech industry experience. He was most recently chief operating officer and chief technical officer at NKGen Biotech where he led technical operations and the build out of the company’s clinical GMP manufacturing facility.
 
Previously, he was senior vice president of Quality and Technical Operations at NKGen Biotech. Before joining NKGen Biotech, he was senior director of Quality Assurance and Quality Control at ARMO Biosciences. Previously, he was director of Quality Assurance at Kite Pharma.
 
Chen started his career with over a decade of increasing responsibility in technical operations at Baxter BioScience. He earned an MBA from the University of Southern California’s Marshall School of Business and a Bachelor of Science in biochemistry/cell biology from the University of California, San Diego.
 
“I have witnessed Tevogen Bio’s rapid growth and disruptive technological advances in the cell and gene therapy space and am excited to join a team who values scientific innovation and embraces a new brand of operational efficiency,” Chen said.

Sadiq Khan, Global Commercial Lead

Sadiq Khan, MBA, brings over 30 years of commercial leadership, operations, and alliance management experience. Most recently, Khan served as executive director of Operations & Business Planning at BioCentriq where he played a key role in the creation of the CDMO specializing in cell and gene therapy manufacturing.
 
Over the course of his career at Sanofi-Aventis and its predecessor companies, Khan successfully launched and managed multiple products in individual markets, regions, and globally. His experience covers over 12 therapeutic areas from specialty brands to blockbuster franchise with annual sales exceeding $1.4 billion.
 
In addition to several country and regional commercial leadership roles in the Asia-Pacific region, he has held U.S. and global franchise leadership positions. Khan holds an undergraduate degree in mathematics and physics, and an MBA cum laude from University of Illinois at Chicago. He has been a regular guest speaker on topics related to biopharmaceutical commercialization, marketing, and alliance management at the Martin Tuchman School of Management at NJIT and the School of Engineering at Columbia University.
 
“Tevogen’s proprietary cell and gene therapy platforms with potential cures for hard-to-treat viral infections, neurological diseases, and cancers give me hope to finally offer accessible treatment options to the community. I am very excited to join this team of professionals where innovative ideas don’t have to wait too long to become a reality,” said Khan.